Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Outperform on Opendoor Technologies, Lowers Price Target to $24

Credit Suisse analyst Stephen Ju maintains Opendoor Technologies (NASDAQ:OPEN) with a Outperform and lowers the price target from $30 to $24.

byBenzinga Newsdesk

May 6, 2022

1 minute read

Credit Suisse analyst Stephen Ju maintains Opendoor Technologies (NASDAQ:OPEN) with a Outperform and lowers the price target from $30 to $24.

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data For DFD-29

By Benzinga Newsdesk

Today, 5:59 AM

Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of

DERM

Roche’s Polivy Combo Regime Under FDA Review For Type Of Blood Cancer

By Vandana Singh

Today, 5:59 AM

Roche Holdings AG (OTC:RHHBY) announced that the FDA accepted its supplemental marketing application for Polivy. Polivy is being developed by Roche…

RHHBF

Evercore ISI Group Downgrades Marriott Intl to In-Line, Raises Price Target to $160

By Benzinga Newsdesk

Today, 5:59 AM

Evercore ISI Group downgrades Marriott Intl (NASDAQ:MAR) from Outperform to In-Line and raises the price target from $145 to $160.

MAR

FDA Advisory Committee Gives Thumbs Up To TransMedics’ OCS Liver System

By Vandana Singh

Today, 5:59 AM

The Gastroenterology and Urology Devices Panel of the FDA’s Medical Devices Advisory Committee has issued a favorable vote to…

TMDX

Credit Suisse Maintains Outperform on Opendoor Technologies, Lowers Price Target to $24

Related Posts

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data For DFD-29

Roche’s Polivy Combo Regime Under FDA Review For Type Of Blood Cancer

Evercore ISI Group Downgrades Marriott Intl to In-Line, Raises Price Target to $160

FDA Advisory Committee Gives Thumbs Up To TransMedics’ OCS Liver System